These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11315038)

  • 21. Deliberate self-poisoning following fluvoxamine-neuroleptics combination.
    Chong SA; Cheong A
    J Clin Psychiatry; 1999 Dec; 60(12):869. PubMed ID: 10665638
    [No Abstract]   [Full Text] [Related]  

  • 22. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding.
    Gentile S
    Arch Womens Ment Health; 2006 May; 9(3):158-9. PubMed ID: 16683078
    [No Abstract]   [Full Text] [Related]  

  • 23. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Likelihood methods for incomplete longitudinal binary responses with incomplete categorical covariates.
    Lipsitz SR; Ibrahim JG; Fitzmaurice GM
    Biometrics; 1999 Mar; 55(1):214-23. PubMed ID: 11318157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
    Pratheesh PJ; Praharaj SK; Srivastava A
    Psychopharmacol Bull; 2011; 44(1):70-3. PubMed ID: 22506441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
    Preskorn SH
    J Psychiatr Pract; 2005 May; 11(3):192-6. PubMed ID: 15920392
    [No Abstract]   [Full Text] [Related]  

  • 27. Fluvoxamine in the treatment of corticosteroid-induced obsessive-compulsive disorder.
    Oulis P; Masdrakis VG; Florakis A; Papadimitriou GN
    Clin Neuropharmacol; 2009; 32(3):176-7. PubMed ID: 19483493
    [No Abstract]   [Full Text] [Related]  

  • 28. Serotonin-selective reuptake inhibitor-induced enuresis in three pediatric cases.
    Hergüner S; Kilinçaslan A; Görker I; Tüzün U
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):367-9. PubMed ID: 17630870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pattern-mixture models for multivariate incomplete data with covariates.
    Little RJ; Wang Y
    Biometrics; 1996 Mar; 52(1):98-111. PubMed ID: 8934587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Haffmans PM; Timmerman L; Hoogduin CA
    Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
    [No Abstract]   [Full Text] [Related]  

  • 32. Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine.
    Stirnimann G; Petitprez S; Abriel H; Schwick NG
    Europace; 2010 Feb; 12(2):282-3. PubMed ID: 19875396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease.
    Gönül AS; Aksu M
    J Clin Psychiatry; 1999 Jun; 60(6):410. PubMed ID: 10401924
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical impact of fluvoxamine-mediated long QTU syndrome.
    Nia AM; Dahlem KM; Gassanov N; Hungerbühler H; Fuhr U; Er F
    Eur J Clin Pharmacol; 2012 Jan; 68(1):109-11. PubMed ID: 21713517
    [No Abstract]   [Full Text] [Related]  

  • 35. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment.
    Silver H; Nassar A; Aharon N; Kaplan A
    Int Clin Psychopharmacol; 2003 Mar; 18(2):87-92. PubMed ID: 12598819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluvoxamine. A review of its safety profile in world-wide studies.
    Wagner W; Zaborny BA; Gray TE
    Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Differential features of SSRIs].
    Cervera S
    Rev Med Univ Navarra; 1997; 41(4):245-57. PubMed ID: 10420965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SSRIs and mammoplasia.
    Marcus P
    Am J Psychiatry; 2001 Jun; 158(6):967. PubMed ID: 11384918
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluvoxamine and sleep disturbances in posttraumatic stress disorder.
    Neylan TC; Metzler TJ; Schoenfeld FB; Weiss DS; Lenoci M; Best SR; Lipsey TL; Marmar CR
    J Trauma Stress; 2001 Jul; 14(3):461-7. PubMed ID: 11534878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.